INMB,our low-float Nasdaq listed Biotech alert, Zero Debt, $19PT
=====================
INmune Bio Inc. (INMB)
Alert Price: $5.60
Float: 3.58M
Corporate Presentation
Must Watch Interview w/ CEO Raymond J. Tesi MD at Nasdaq.
Fact Sheet
12-Month Consensus Price Target: $19.00 (Zacks Small-Cap Research)
Website | Recent News
========================
Members,
Before we get into our next great trade idea, we want to congratulate all of our members who acted on yesterday's trade alert, and secured the up to +42% in realistic gains it delivered over the past two days!
We are keeping our pedal to the metal and releasing an even more exciting (and possibly more profitable) trade idea.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INMB could probably be the most attractive biotech company listed on the Nasdaq exchange that you've never heard of.
But we don't believe that INMB will be flying under the radar for much longer.
The Company's CEO Raymond J. Tesi MD was just interviewed at Nasdaq, and we loved what he had to say.
Dr . Tesi highlighted the recent developments in INMBs programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease.
He also discussed reaching new milestones in the development of therapies that target the innate immune system which we will cover in this report.
Once you've listened to the interview, we think you'll agree that the future appears very bright for INMB, and that the best is yet to come.
INMB: Harnessing the Power of the Innate Immune System
INMBs therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
NASH - A progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595, and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. IMmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Company Highlights:
Public clinical stage immunology company
In 2020 - 2 Phase II programs and 2 Phase I programs
Efficient use of capital and funding sources to maximize run-way
Opportunity to add clinical programs as resources become available
Two product platforms targeting innate immune dysfunction
Programs in cancer, AD and NASH
Product platform technologies provide multiple strategic opportunities
Experienced management team
Multiple programs provide sum-of-parts value
Upcoming Milestones for INMB
3Q19 – First patient enrolled XPro1595 AD trial
1H20 – initiate NeuLiv Phase II NASH cancer trial
1H20 – initiate INB03 combination Phase II cancer trial
2H20 – XPro1595 AD Phase I trial data
4Q20 – first patient enrolled (INKMUNE) cancer trial
The Bullish Case for INMB
Has Zero Debt
Trades on the NASD exchange
Has an extremely tight float (3.58M)
Is trading well under analyst’s price targets, with plenty of room to the upside. (Zacks Small-Cap Research has a $19 PT for INMB, an upside of over +239% from today's alert price.)
Has witnessed some heavy insider buying as of late.
United States Patent and Trademark Office (USPTO) has given formal notice of allowance to Patent Application Serial No. 15/776,061, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR”,
Which covers (INKmune’s) INB03 Program utilizing dominant negative TNFA (DN-TNFA) technology for treating cancer.
Is presenting at the upcoming Alzheimer’s Association International Conference (AAIC) Satellite Symposium held Sept. 25 – 27 in Sydney, Australia.
Get to Know INMB Impressive Pipeline
Inkmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH.
Inkmune -Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
NeuLiv - May enable INMB to target the underlying cause of NASH, to help stop the disease and allow the liver to heal “NASH presents a significant unmet medical need. We believe NeuLiv™ may enable us to target the underlying cause of NASH, to help stop the disease and allow the liver to heal,” said RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “NeuLiv precisely targets soluble TNF, a key cytokine driving pathologic chronic inflammation. Unlike treatments focused on addressing fibrosis directly, we believe NeuLiv™ targets peripheral, regional and local causes of innate immune dysfunction that lead to chronic inflammation in patients with NASH. We hope this strategy will prevent progression of the disease and allow hepatic repair mechanisms to function.”
Innate immune dysregulation, also called chronic inflammation, is a low-grade inflammatory state that, over time, has detrimental effects on organs, including the liver and brain. NeuLiv™, which is the third drug development program originating from INmune Bio’s DN-TNF platform, is a next generation TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. By targeting soluble TNF, NeuLiv may alter the complex immunobiology that causes the development and progression of NASH.
NASH is a progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• NeuLiv – NASH market
– Market size >$7B
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
Three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in INMB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on INMB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In INMB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc . boosted its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc .’s holdings in INmune Bio were worth $29,000 at the end of the most recent reporting period. 0.36% of the stock is owned by hedge funds and other institutional investors.
Major shareholder Mark William Lowdell purchased 2,918 shares of INmune Bio stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average cost of $6.23 per share, with a total value of $18,179.14.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within?
Tiny Float = Big Move Potential
The public float for INMB is just 3.58M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time INMB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades At $5.60 And Has A $19 Price Target
Zacks Small-Cap Research recently initiated coverage of INmune Bio, Inc. (NASDAQ:INMB) with a $19 valuation. INmune is a biopharmaceutical company developing therapies that target the innate immune system to treat cancer. In contrast to the adaptive immune system, which relies upon a highly targeted response to specific antigens, the innate immune system is designed to deliver a non-specific response to abnormal cells or foreign antigens. The company targets myeloid derived suppressor cells (MDSC) and natural killer ( NK ) cells through its lead development products, INB03 and INKmune. INB03 is designed to inhibit soluble tumor necrosis factor (sTNF), a key signaling molecule for MDSC activation while INKmune provides the necessary priming signal to convert NK cells from a ‘resting’ to an ‘active’ state. In addition to the two cancer therapies, INmune is also developing XPro1595 (which has a similar MOA as INB03) as a treatment for mild to moderate Alzheimer’s Disease.
Upcoming catalysts for the company include:
INB03 – A Phase 1 monotherapy trial is currently underway. This trial will transition to a combination therapy clinical trial in the summer of 2019. A Phase 2 clinical trial testing INB03 with checkpoint inhibitors in patients who are resistant to checkpoint inhibitor therapy will initiate in 2020.
XPro1595 – We anticipate a Phase 1 clinical trial in patients with Alzheimer’s disease will initiate in the summer of 2019. This study is supported by a $1 million grant from the Alzheimer’s Association.
INKmune – A Phase 1/2 clinical trial will initiate later in 2019 in patients with relapsed/refractory ovarian cancer.
With an upside of over +239%, now could be the perfect time to start building a position in INMB.
Recent Developments
CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress
Yesterday, the Company announced that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company’s accomplishments. The interview can be found by clicking here.
“Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” said Dr . Tesi. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.”
INmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH.
Additionally, CJ Barnum, Ph .D., Director of Neuroscience, will present on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress on Oct. 16 in Switzerland
Technical Analysis
We've done our very own chart analysis on INMB, and see the potential for a move of over 60%!
Bollinger Bands Have Tightened Signaling a Comprehensive Move Imminent
Sell Volume Declining
Very Strong Reversal of the Lows
Bullish H&S Forming
RSI in Oversold Territory
The stock has seen multiple bounces and reversals throughout its short history, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
We love the CEO's vision for the future.
With its low-float, INMB could see a huge run-up on volume .
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
*Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $10,000 cash for a 1-day marketing contract for INMB. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
INmune Bio Inc. (INMB)
Alert Price: $5.60
Float: 3.58M
Corporate Presentation
Must Watch Interview w/ CEO Raymond J. Tesi MD at Nasdaq.
Fact Sheet
12-Month Consensus Price Target: $19.00 (Zacks Small-Cap Research)
Website | Recent News
========================
Members,
Before we get into our next great trade idea, we want to congratulate all of our members who acted on yesterday's trade alert, and secured the up to +42% in realistic gains it delivered over the past two days!
We are keeping our pedal to the metal and releasing an even more exciting (and possibly more profitable) trade idea.
Please turn your immediate attention to INmune Bio Inc. (INMB).
INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INMB could probably be the most attractive biotech company listed on the Nasdaq exchange that you've never heard of.
But we don't believe that INMB will be flying under the radar for much longer.
The Company's CEO Raymond J. Tesi MD was just interviewed at Nasdaq, and we loved what he had to say.
Dr . Tesi highlighted the recent developments in INMBs programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease.
He also discussed reaching new milestones in the development of therapies that target the innate immune system which we will cover in this report.
Once you've listened to the interview, we think you'll agree that the future appears very bright for INMB, and that the best is yet to come.
INMB: Harnessing the Power of the Innate Immune System
INMBs therapies provide treatment for diseases that effect millions of patients each year.
Alzheimer’s Disease – The Alzheimer’s disease therapeutics market will grow to be worth more than $12 billion annually by 2026.
Cancer Residual Disease – About 1.7 million patients are affected by this every year, with nearly 610,000 patients dying as a result.
Checkpoint Inhibitor Market – The global checkpoint inhibitor market will grow to be worth more than $40 billion annually by the year 2026.
NASH - A progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer’s (XPro595, and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. IMmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Company Highlights:
Public clinical stage immunology company
In 2020 - 2 Phase II programs and 2 Phase I programs
Efficient use of capital and funding sources to maximize run-way
Opportunity to add clinical programs as resources become available
Two product platforms targeting innate immune dysfunction
Programs in cancer, AD and NASH
Product platform technologies provide multiple strategic opportunities
Experienced management team
Multiple programs provide sum-of-parts value
Upcoming Milestones for INMB
3Q19 – First patient enrolled XPro1595 AD trial
1H20 – initiate NeuLiv Phase II NASH cancer trial
1H20 – initiate INB03 combination Phase II cancer trial
2H20 – XPro1595 AD Phase I trial data
4Q20 – first patient enrolled (INKMUNE) cancer trial
The Bullish Case for INMB
Has Zero Debt
Trades on the NASD exchange
Has an extremely tight float (3.58M)
Is trading well under analyst’s price targets, with plenty of room to the upside. (Zacks Small-Cap Research has a $19 PT for INMB, an upside of over +239% from today's alert price.)
Has witnessed some heavy insider buying as of late.
United States Patent and Trademark Office (USPTO) has given formal notice of allowance to Patent Application Serial No. 15/776,061, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NECROSIS FACTOR”,
Which covers (INKmune’s) INB03 Program utilizing dominant negative TNFA (DN-TNFA) technology for treating cancer.
Is presenting at the upcoming Alzheimer’s Association International Conference (AAIC) Satellite Symposium held Sept. 25 – 27 in Sydney, Australia.
Get to Know INMB Impressive Pipeline
Inkmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH.
Inkmune -Cancer - in oncology patients that relapse, cells that are known to target residual cancer cells, fail to eliminate the remainder of the disease after treatment. INMB is working to keep this from happening with INKmune.
INB03-Alzheimers - targets myeloid derived suppressor cells, or MDSC, believed to be the reason that many cancer patients do not respond to checkpoint inhibitor treatments.
XPro1595-Cancer – is under development as a potential option for patients with Alzheimer’s disease, believed to be caused by neuroinflammation of brain cells. The company believes XPro1595 will inhibit neuroinflammation and the resultant cell death.
NeuLiv - May enable INMB to target the underlying cause of NASH, to help stop the disease and allow the liver to heal “NASH presents a significant unmet medical need. We believe NeuLiv™ may enable us to target the underlying cause of NASH, to help stop the disease and allow the liver to heal,” said RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “NeuLiv precisely targets soluble TNF, a key cytokine driving pathologic chronic inflammation. Unlike treatments focused on addressing fibrosis directly, we believe NeuLiv™ targets peripheral, regional and local causes of innate immune dysfunction that lead to chronic inflammation in patients with NASH. We hope this strategy will prevent progression of the disease and allow hepatic repair mechanisms to function.”
Innate immune dysregulation, also called chronic inflammation, is a low-grade inflammatory state that, over time, has detrimental effects on organs, including the liver and brain. NeuLiv™, which is the third drug development program originating from INmune Bio’s DN-TNF platform, is a next generation TNF inhibitor that neutralizes soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors. By targeting soluble TNF, NeuLiv may alter the complex immunobiology that causes the development and progression of NASH.
NASH is a progressive disease caused by excessive fat accumulation in the liver that induces chronic inflammation, resulting in fibrosis that can lead to cirrhosis, liver failure, cancer and death. By 2020, NASH is projected to become the leading cause of liver transplants in the U.S. No medications are currently approved for the treatment of the disease.
INMB's Pipeline's Multi-Billion Dollar Market Opportunity
• NeuLiv – NASH market
– Market size >$7B
• XPro1595 - Alzheimer’s/dementia market*
– 5.8 M patients in US
– 2019 est cost to care for US AD patients $280B
• INKmune
- Cancer residual disease market **
– 1,735,350 new cases and 609,640 people will die
– Initial targets: Ovarian Cancer and High Risk MDS
• INB03
- Resistance to Checkpoint Inhibitors market***
– CPI’s work 27% of patients. CPI 2025 est market size $56B
– INB03 in combination with CPI’s should increase the number of patients sensitive to CPIs. – Initial targets: Melanoma and Renal Cell Cancer
Three of the candidates in the company’s pipeline are either currently in Phase 1 clinical studies or are about to begin Phase 1 clinical studies in the near term.
INB03 Australia Solid Tumors Initial Phase 1 Data Readout- Q3 ’19
INKmune UK Ovarian Cancer Initiate Enrollment of Phase 1/2 study - Q4 ’19
INB03 Australia Solid Tumors Initiate Combination Study, Additional Cohorts to Phase 1 Study- 1H ’20
XPro1595 UK Alzheimer’s Initiate Enrollment of Phase 1 Study - Q3’19
INKmune UK Ovarian Cancer Report Initial Phase 1 Data - 1H ’20
XPro1595 UK Alzheimer’s Early Data - Q1’20
INKmune UK Ovarian Cancer Initiate Phase 2 Study - 2H ’20
INB03 Australia/US Solid Tumors Initiate INB03 + CPI* Phase 2 Combination Study - 1H ’20
The Alzheimer Association believes in INMB
In order to advance XPro1595 in the treatment of AD, INmune was recently awarded a $1 million grant from the Alzheimer’s Association.
The grant will support a biomarker-directed Phase 1 clinical trial in 18 patients with mild-to-moderate AD. XPro1595 will be administered subcutaneously once a week for three months and biomarkers of inflammation will be assessed at 0, 6, and 12 weeks.
This ringing endorsement from the Alzheimer Association should have potential investors sold on INMB's potential to help treat this dreaded disease that effects 5.8M patients in the U.S. alone.
The Smart Money Is Buying Up Shares In INMB
Insiders own 63% of the outstanding shares of INMB.
Insiders have spent $770,000 buying up company shares in the past two months.
An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc . boosted its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc .’s holdings in INmune Bio were worth $29,000 at the end of the most recent reporting period. 0.36% of the stock is owned by hedge funds and other institutional investors.
Major shareholder Mark William Lowdell purchased 2,918 shares of INmune Bio stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average cost of $6.23 per share, with a total value of $18,179.14.
The Company has zero debt!
The fact that insiders own 63% of the shares, has us bullish on INMB's growth potential.
Who would know better if the Company was undervalued than those working within?
Tiny Float = Big Move Potential
The public float for INMB is just 3.58M
A float that low is a rarity for companies listed on the NASDAQ.
It also means the IMNB could moonshot if it were to see an increase in daily volume .
In fact, the first time INMB broke over 100K in daily volume , its shares had their biggest single day move, climbing from $8.80 to $10.68, for a single day gain of over +21%!
INMB Trades At $5.60 And Has A $19 Price Target
Zacks Small-Cap Research recently initiated coverage of INmune Bio, Inc. (NASDAQ:INMB) with a $19 valuation. INmune is a biopharmaceutical company developing therapies that target the innate immune system to treat cancer. In contrast to the adaptive immune system, which relies upon a highly targeted response to specific antigens, the innate immune system is designed to deliver a non-specific response to abnormal cells or foreign antigens. The company targets myeloid derived suppressor cells (MDSC) and natural killer ( NK ) cells through its lead development products, INB03 and INKmune. INB03 is designed to inhibit soluble tumor necrosis factor (sTNF), a key signaling molecule for MDSC activation while INKmune provides the necessary priming signal to convert NK cells from a ‘resting’ to an ‘active’ state. In addition to the two cancer therapies, INmune is also developing XPro1595 (which has a similar MOA as INB03) as a treatment for mild to moderate Alzheimer’s Disease.
Upcoming catalysts for the company include:
INB03 – A Phase 1 monotherapy trial is currently underway. This trial will transition to a combination therapy clinical trial in the summer of 2019. A Phase 2 clinical trial testing INB03 with checkpoint inhibitors in patients who are resistant to checkpoint inhibitor therapy will initiate in 2020.
XPro1595 – We anticipate a Phase 1 clinical trial in patients with Alzheimer’s disease will initiate in the summer of 2019. This study is supported by a $1 million grant from the Alzheimer’s Association.
INKmune – A Phase 1/2 clinical trial will initiate later in 2019 in patients with relapsed/refractory ovarian cancer.
With an upside of over +239%, now could be the perfect time to start building a position in INMB.
Recent Developments
CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress
Yesterday, the Company announced that RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company’s accomplishments. The interview can be found by clicking here.
“Nasdaq’s MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer’s disease and nonalcoholic steatohepatitis (NASH) liver disease,” said Dr . Tesi. “We hope to continue reaching new milestones in the development of therapies that target the innate immune system.”
INmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer’s disease; and NeuLiv™ for the treatment of NASH.
Additionally, CJ Barnum, Ph .D., Director of Neuroscience, will present on “Approaching Alzheimer’s disease as an immunological disease: role of biomarkers” at the World Immunotherapy Congress on Oct. 16 in Switzerland
Technical Analysis
We've done our very own chart analysis on INMB, and see the potential for a move of over 60%!
Bollinger Bands Have Tightened Signaling a Comprehensive Move Imminent
Sell Volume Declining
Very Strong Reversal of the Lows
Bullish H&S Forming
RSI in Oversold Territory
The stock has seen multiple bounces and reversals throughout its short history, which leads us to believe that now may be the perfect entry point for those looking to capitalize on INMB's next potential chart reversal.
The Bottom-Line
We don't think INMB will be trading under the radar for much longer.
We love the CEO's vision for the future.
With its low-float, INMB could see a huge run-up on volume .
ZERO Debt and Heavy Insider Ownership have us bullish heading into the 2nd half of 2019.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
*Past performance is not an indicator of future returns. The publishers of this report are not investment advisors and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. The publishers of this report have received compensation from a third party of USD $10,000 cash for a 1-day marketing contract for INMB. Never make investment decisions based on anything the publisher of this report says. This message is meant for informational and educational purposes only and does not provide investment advice.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media